We are committed to providing access to affordable and innovative medicines, driven by our purpose of ‘Good Health Can’t Wait’.

Our products and services are spread across our core businesses of Active Pharmaceutical Ingredients (API), generics, branded generics, biosimilars and over-the-counter pharmaceutical products around the world. We work towards meeting unmet patients needs in the areas of gastro-enterology, cardiovascular, diabetology, oncology, pain management and dermatology. We are investing in businesses of the future including drug discovery, clinically-differentiated assets and digital healthcare.

We started in 1984 with a modest investment and a bold vision.
Today, with research and development centres, manufacturing facilities and commercial
presence across the globe, we serve over half a billion patients worldwide. We aspire to
triple our reach and touch over 1.5 billion patients by 2030.

0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
countries
0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
nationalities
USD
0
2
3
4
5
6
7
8
9
0
.
0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
bn
Revenue (As of FY '24)
0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
.
0
2
3
4
5
6
7
8
9
0
%
EBITDA (As of FY '25)
0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
,
0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
0
2
3
4
5
6
7
8
9
0
+
employees

Good Health Can’t Wait

Our purpose is to provide access to affordable and innovative medicines and healthcare solutions. Read more about our purpose, principles and values.

Our core tenets

Pioneering work based on science
Our deep science capabilities form the bedrock of our work enabling us to innovate for patients. Our investment in complex chemistry and biology have led us to several firsts. In India, we were among the first to export APIs at scale and introduce many new molecules. We were the first in India to initiate novel drug discovery in the 1990s and to receive 180-day exclusivity from the USFDA in the 2000s. We focus on being first to market, helping us deliver on our promises.
Progressive People Practices
We have pioneered practices such as ‘Self-Managed Teams’ in pharma. We develop leaders through our initiatives such as our ‘New Horizons Leadership Programme’. Our investment in people capabilities serves not just our company but also the industry. We have set bold goals for ourselves in our diversity, equity and inclusion journey. We aspire to create an environment in which people can realise their full potential through work and continuous learning.
Rigour in Governance
We were the first Asian pharma company outside Japan to list on the New York Stock Exchange in 2001. We are committed to the highest standards of compliance, ethics and quality in every activity that we undertake. We are consistently recognised by our stakeholders for our governance. We endeavour to set the bar high and maintain the trust our stakeholders repose in us. We continue to work on progressive and timely disclosures, transparent policies and processes.

Our current ESG goals


Reducing Carbon Emissions

  • 100% renewable power by 2030
  • Carbon neutrality in our direct operations (scope 1 and 2 emissions) by 2030
  • 12.5% reduction in indirect carbon emissions (Scope 3 emissions) by 2030

Water Positivity

  • Become water positive by 2025

#WeAreDrReddys